Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Modulation of the Nrf2/Keap1 Pathway by N-Acetylcysteine: A Key Mechanism in the Prevention of Experimental Hepatocellular Carcinoma

ABSTRACT: Background & Aims: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, marked by dysregulated cellular processes and limited treatment options. N-acetylcysteine (NAC), widely used for acetaminophen overdose and as a mucolytic agent, has not been mechanistically characterized in HCC. We evaluated the effects of NAC in experimental HCC, including its role in modulating the Nrf2/Keap1 signaling pathway Methods: HCC was induced in male Fischer-344 rats using diethylnitrosamine (DEN) and 2-acetylaminofluorene (2-AAF), with daily NAC administration for 16 weeks. In parallel, HepG2 cells were used to evaluate the cytoprotective effects of NAC in vitro. Biochemical, molecular, transcriptomic, and histological analyses were performed. Results: NAC exerted hepatoprotective effects that limited protumorigenic progression, fibrosis, and tumor cell proliferation. Notably, NAC modulated the Nrf2/Keap1 pathway, enhancing antioxidant defenses and preserving biomolecular integrity. Conclusions: NAC modulates key cellular processes involved in HCC development, supporting its repositioning as a potential adjuvant therapeutic strategy.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE316853 | GEO | 2026/02/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Chronic activation of hepatic Nrf2 has no major effect on fatty acid and glucose metabolism in adult mice

Project description:The transcription factor NF-E2-related factor 2 (Nrf2) induces cytoprotective genes, but has also been linked to the regulation of hepatic energy metabolism. In order to assess the pharmacological potential of hepatic Nrf2 activation in metabolic disease, Nrf2 was activated over 8 weeks in mice on Western diet using two different siRNAs against kelch-like ECH-associated protein 1 (Keap1), the inhibitory protein of Nrf2. Whole genome expression analysis followed by pathway analysis demonstrated that the suppression of Keap1 expression induced genes that are involved in anti-oxidative stress defense and biotransformation, pathways proving the activation of Nrf2 by the siRNAs against Keap1. The expression of neither fatty acid- nor carbohydrate-handling proteins was regulated by the suppression of Keap1. Metabolic profiling of the animals did also not show effects on plasma and hepatic lipids, energy expenditure or glucose tolerance by the activation of Nrf2. The data indicate that hepatic Nrf2 is not a major regulator of intermediary metabolism in mice. Gene expression profile of mouse liver samples from 8-week-old male C57BL6/J mice (N=24) treated with liver-selective Keap1-specific siRNA (group 1: siKeap1-1, N=8; group 2: siKeap1-2, N=8) or unspecific scrambled control siRNA (group 3: siControl, N=8)

2016-09-01 | E-GEOD-80956 | biostudies-arrayexpress

Expression data from Keap1 overexpression and Nrf2 knockdown lung cancer cell

Project description:Keap1 overexpressed and Nrf2 depleted CL1-5 cells were used to identify genes regulated by Keap1/Nrf2 axis-dependent gene regulations We used microarrays to detail the global programme of gene expression underlying metastasis and identified distinct classes of Keap1/Nrf2-regulated genes during this process. CL1-5 cells stably expressed Keap1 expressing construct and Nrf2-specific shRNA were analyzed compared to control cells

2015-03-04 | E-GEOD-66473 | biostudies-arrayexpress

The Keap1-Nrf2-Bach1 signaling mediates UBR7 negative regulation of HK2 to inhibit glycolysis and HCC tumorigenesis [RNA-seq]

Project description:We found that Keap1-Nrf2 signaling pathway mediates UBR7 to regulate HK2 expression through the modification of histone H2BK120 monoubiquitination, thereby inhibiting glycolysis and HCC tumorigenesis.

2022-12-09 | GSE173501 | GEO

The Keap1-Nrf2-Bach1 signaling mediates UBR7 negative regulation of HK2 to inhibit glycolysis and HCC tumorigenesis

2022-12-09 | GSE173454 | GEO

The rat lncRNA and mRNA microarray analysis of the 6 samples from2-AAF/PH group and Diwu Yanggan capsule treatment group

Project description:In some previous studies, DWYG played key roles in improving immune-modulatory responses, ameliorating liver lesions, enhancing liver regeneration, virus-killing activities and HCC inhibition. It has been shown that liver injury caused by an array of factors, can significantly hinder the regenerative effects of mature hepatocytes on liver parenchyma. However, factors such as 2-acetylaminofluorene (2-AAF) induce hepatocyte injury to limit the regenerative ability of liver. In addition, 2-AAF exposure results in cell lysis and disrupts other liver functions. These have made the 2-AAF/PH animal model the most commonly used in assessing the mechanisms by which medicines exert therapeutic effects. In our previous study, it has been demonstrated that DWYG could control HCC in 2-AAF/PH rats, potentially through the modulation and restoration of the liver regeneration microenvironment.However, the comprehensive mechanisms of 2-AAF/PH-induced rat pathogenesis and the pharmacological mechanisms of DWYG is still poorly understood. The present study there aims to explore the mechanisms by which DWYG regulates hepatic transcriptome in a 2-AAF/PH-induced rat model in view of enhancing its applications in liver treatment.

2020-06-03 | GSE151614 | GEO

Non-small cell lung cancer-associated Keap1 mutations lead to epigenetic reprogramming and tumorigenesis through CHD6 stabilization

Project description:The E3 ubiquitin ligase substrate recognition subunit Keap1 mediates the ubiquitination and degradation of the oxidative stress transcription factor NRF2. Approximately 30% of non-small cell lung cancers (NSCLCs) harbor inactivating mutations in Keap1 or activating mutations in NRF2, both of which lead to the stabilization of NRF2 and activation of the downstream antioxidant pathway. Recent studies have found that the oncogenic effects of Keap1 and NRF2 mutations are not entirely equivalent, suggesting that Keap1 may have other regulatory substrates. In previous work, we used affinity immunopurification and mass spectrometry to identify the epigenetic regulator CHD6 as a Keap1-interacting protein, with Keap1 mediating the ubiquitination and degradation of CHD6. NSCLC-derived Keap1 mutants lost the ability to bind and ubiquitinate CHD6. Additionally, CHD6 interacts with NRF2 and promotes the enrichment of NRF2 at the promoters of its target genes, enhancing their transcription.This project aims to elucidate the mechanism by which the abnormal accumulation of CHD6 protein, due to disruption of its Keap1-mediated degradation, drives epigenetic reprogramming in the context of Keap1-mutant NSCLC development and progression. The findings will provide a theoretical basis for the development of NRF2 pathway inhibitors targeting CHD6 as a drug target.

2025-01-01 | GSE284431 | GEO

Transcription profiling of mouse liver from conditional Keap1 knockout mice vs. genetic control mice

Project description:To compare hepatic gene expression in conditional Keap1 knockout (Alb-Cre:Keap1(flox/-)) and genetic control mice. Disruption of Keap1-mediated repression of Nrf2 signaling was expected to result in increased expression of Nrf2-regulated genes. Experiment Overall Design: Hepatic gene expression was compared in conditional Keap1 knockout and genetic control mice (Alb-Cre:Keap1(flox/+)) mice. Male 9 week old mice were used, n=3/group.

2008-06-11 | E-GEOD-11287 | biostudies-arrayexpress

Whole esophagi of WT, Nrf2-/- and Keap1-/- mice on C57BL background at E11.5, E15.5, P0 and P7, and esophageal epithelium of adult (8 weeks old) mice

Project description:Transcriptional profiling of mouse esophageal development. Goal was to globally profile critical genes and signaling pathways during the development of mouse esophagus and determine how Nrf2/Keap1 pathway regulates the morphogenesis of the esophageal epithelium. Mutiple-comparison. WT-E11.5 vs. WT-E15.5 vs. WT-P0 vs. WT-P7; WT-P7 vs. WT-adult; WT-adult vs. Nrf2-/--adult; WT-P7 vs. Nrf2-/--P7 vs. Keap1-/--P7 vs. Nrf2-/-Keap1-/--P7. Biological replicates: 3 replicates for each group.

2011-12-09 | E-GEOD-34278 | biostudies-arrayexpress

A Metabolic Switch Controlling Liver Cancer Evolution from Senescent NASH Hepatocytes

Project description:Hepatocellular carcinoma (HCC) originates from differentiated hepatocytes undergoing compensatory proliferation in livers damaged by viruses or nonalcoholic steatohepatitis (NASH). While increasing HCC risk, NASH triggers TP53-dependent hepatocyte senescence, which we found to parallel hypernutrition-induced DNA breaks. How this tumor-suppressive response is bypassed to license accumulation of oncogenic mutations and enable HCC progression was previously unknown. We identified the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) as a TP53 target that is elevated in senescent-like NASH hepatocytes but suppressed through promoter hypermethylation and proteasomal degradation in most human HCCs. FBP1 first declines in metabolically-stressed premalignant disease-associated hepatocytes and HCC progenitor cells, paralleling the protumorigenic activation of AKT and NRF2. By accelerating FBP1 and TP53 degradation AKT and NRF2 enhance the proliferation and metabolic activity of previously senescent HCC progenitors. The senescence-reversing NRF2-FBP1-AKT-TP53 metabolic switch, operative in mice and humans, also enhances proliferation-enabled accumulation of DNA damage-induced somatic mutations that drive NASH to HCC progression.

2025-01-10 | GSE266447 | GEO

Characterization of RA839, a non-covalent small-molecule binder to Keap1 and selective activator of Nrf2 signalling

Project description:The activation of the transcription factor NF-E2-related factor 2 (Nrf2) maintains cellular homeostasis in response to oxidative stress by the regulation of multiple cytoprotective genes. Without stressors the activity of Nrf2 is inhibited by its interaction with the kelch-like ECH-associated protein 1 (Keap1). Here, we describe RA839, a small molecule that binds non-covalently to the Nrf2-interacting kelch domain of Keap1 with a Kd of approximately 6 µM, as demonstrated by X-ray co-crystallization and isothermal titration calorimetry. Whole-genome DNA arrays showed that at 10 µM RA839 significantly regulated 105 genes in bone marrow-derived macrophages. Canonical pathway mapping of these genes revealed an activation of pathways linked with Nrf2 signalling. These pathways were also activated after the activation of Nrf2 by the silencing of Keap1 expression. RA839 regulated only two genes in Nrf2 knockout macrophages. Similar to the activation of Nrf2 by either silencing of Keap1 expression or by the reactive compound CDDO-Me, RA839 prevented the induction of both inducible nitric oxide synthase expression and nitric oxide release in response to lipopolysaccharides in macrophages. In mice RA839 acutely induced Nrf2-target gene expression in liver. RA839 is a selective inhibitor of the Keap1/Nrf2 interaction and a useful tool compound to study the biology of Nrf2. Gene expression profile of bone marrow derived murine macrophages (BMDM) from Nrf2+/+ or Nrf2-/- mice treated with RA838, siKeap1-1 or siKeap1-2 were compared to untreated DMSO control or siControl. Four biological replicates were used for each sample group.

2015-10-31 | E-GEOD-71695 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data